Comprehensive genetic risk assessment, multi-gene DNA testing, and personalized cancer surveillance protocols planned and guided by Dr. Rishabh Jain, DM Medical Oncology from AIIMS New Delhi. Proactive protection for you and your family.
About 5% to 10% of all cancers are hereditary, caused by an inherited genetic mutation (such as BRCA1, BRCA2, or mismatch repair genes) passed down through families. People who inherit these gene alterations have a significantly higher lifetime risk of developing specific cancers, often at a younger age.
Your genetic history does not define your future. Genetic testing and specialized counselling empower you to take control. As an AIIMS-trained medical oncologist in Jaipur, Dr. Rishabh Jain helps families identify genetic predispositions early, providing structured surveillance, preventive interventions, and mutation-targeted therapy options.
Leading genetic conditions evaluated and managed at Rishabh Cancer Care:
Caused by mutations in BRCA1, BRCA2, PALB2, or ATM genes, increasing risk of breast, ovarian, and prostate cancers.
Mutations in MLH1, MSH2, MSH6, or PMS2 genes causing increased predisposition to colorectal, uterine, and stomach cancers.
APC gene mutation causing hundreds of pre-cancerous polyps in the colon from young adulthood.
Rare hereditary conditions linked to TP53 and PTEN genes associated with early sarcomas, brain, and thyroid tumours.
Genetic evaluation is recommended if you or your family members meet any of the following criteria:
A supportive, confidential 4-step genetic oncology workflow:
Dr. Jain constructs a 3-generation family tree (pedigree) to assess genetic probability and explain test implications.
A quick, painless blood draw or saliva sample collected in our clinic without any special preparation.
DNA sequenced in accredited genomics laboratories covering multi-gene hereditary cancer panels.
Results explained with compassionate clarity, distinguishing between pathogenic mutations and benign variants.
Customized screening schedules (annual MRI breast, early colonoscopy) created for mutation carriers.
For existing cancer patients, BRCA-positive status unlocks targeted PARP inhibitors (Olaparib, Talazoparib).
Testing positive for a gene mutation allows us to implement proven preventive measures:
| Preventive Strategy | Clinical Action & Benefit |
|---|---|
| Intensive Early Screening | Annual Breast MRI + Mammogram starting at age 25–30; Colonoscopy every 1–2 years from age 20–25. |
| Chemoprevention | Medications like Tamoxifen or oral contraceptives to significantly lower future breast/ovarian risk. |
| Risk-Reducing Surgeries | Prophylactic salpingo-oophorectomy (after childbearing) reduces ovarian cancer risk by up to 90%. |
| Targeted Therapy Selection | Direct selection of precision PARP inhibitor tablets for cancer patients with germline BRCA mutations. |
If your family history shows early-onset or repeated cancers, genetic screening can save lives through early detection and proactive prevention. Consult Dr. Rishabh Jain today.
Technological advances in Next-Generation Sequencing (NGS) have made genetic testing highly affordable in India:
BRCA1 & BRCA2 complete gene sequencing at transparent, accessible pricing.
Simultaneous screening of 30 to 50+ hereditary cancer genes for thorough peace of mind.
Once a mutation is found in a patient, family members can test for the specific gene at very low cost.
Your inherited genetic DNA never changes; testing is done only once in a lifetime.
Includes complete pre-test pedigree mapping and post-result clinical consultation.
Secure electronic genomic reports provided with national genetic registry standards.
Trained at AIIMS New Delhi, Dr. Rishabh Jain provides scientific hereditary cancer risk assessment, NGS genetic counselling, and individualized cancer prevention roadmaps for families across Rajasthan.
More about Dr. Jain →Real stories and experiences from patients who underwent chemotherapy treatment with Dr. Rishabh Jain.
"Dr. Rishabh Jain is one of the most knowledgeable cancer specialists in Jaipur. He explains the disease and treatment options very clearly and gives patients a lot of confidence. Highly recommended."
"Dr. Rishabh Jain is highly professional, knowledgeable, and caring. He listens patiently, explains everything clearly, and provides the right treatment. The entire experience was smooth and reassuring. Highly recommended!"
"After meeting several doctors, I finally found the best oncologist in Jaipur. Dr. Rishabh listened carefully to my concerns and guided me with a clear treatment plan. Highly satisfied with the care."
Common questions answered by Dr. Rishabh Jain, DM Medical Oncology.
No. Testing positive means you have an increased lifetime risk, not a certainty. It allows us to put proactive surveillance and prevention plans in place to detect any change at the earliest, curable stage.
It is a simple blood test or saliva swab collected in the clinic. The sample is sent to a specialized genomics lab for high-throughput DNA sequencing.
Comprehensive multi-gene panel reports are typically ready within 2 to 3 weeks, followed by a dedicated post-test consultation with Dr. Jain.
Yes. Men can inherit and pass on BRCA1, BRCA2, and Lynch syndrome mutations to their sons and daughters equally (50% chance per child), and are themselves at risk for prostate and breast cancers.
It directly influences treatment decisions: for instance, identifying a BRCA mutation makes patients eligible for precision PARP inhibitor tablets (like Olaparib) and platinum-based chemotherapy.
Many comprehensive cancer insurance policies and corporate TPAs now cover diagnostic genetic testing when recommended by a medical oncologist.
Talk to Dr. Rishabh Jain, AIIMS-trained cancer specialist in Jaipur, and protect your family's future with genetic oncology.